Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel Free MBX Stock Alerts

Microbix Biosystems (MBX) Competitors

Microbix Biosystems logo
C$0.30 -0.01 (-1.67%)
As of 09/24/2026 03:59 PM Eastern
Compare

MBX vs. IPA, AKU, GEN, LMD, and LXG

Should you buy Microbix Biosystems stock or one of its competitors? Microbix Biosystems's main competitors and comparable companies include ImmunoPrecise Antibodies (IPA), Akumin (AKU), GeneNews (GEN), LED Medical Diagnostics (LMD), and LexaGene (LXG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Microbix Biosystems compare to ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies (CVE:IPA) and Microbix Biosystems (TSE:MBX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

ImmunoPrecise Antibodies has a net margin of 0.00% compared to Microbix Biosystems' net margin of -31.72%. ImmunoPrecise Antibodies' return on equity of 0.00% beat Microbix Biosystems' return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunoPrecise AntibodiesN/A N/A N/A
Microbix Biosystems -31.72%-18.83%3.82%

In the previous week, Microbix Biosystems had 3 more articles in the media than ImmunoPrecise Antibodies. MarketBeat recorded 3 mentions for Microbix Biosystems and 0 mentions for ImmunoPrecise Antibodies. Microbix Biosystems' average media sentiment score of 0.94 beat ImmunoPrecise Antibodies' score of 0.00 indicating that Microbix Biosystems is being referred to more favorably in the news media.

Company Overall Sentiment
ImmunoPrecise Antibodies Neutral
Microbix Biosystems Positive

0.2% of Microbix Biosystems shares are owned by institutional investors. 14.0% of Microbix Biosystems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Microbix Biosystems has lower revenue, but higher earnings than ImmunoPrecise Antibodies. Microbix Biosystems is trading at a lower price-to-earnings ratio than ImmunoPrecise Antibodies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoPrecise AntibodiesC$19.47M8.33-C$22.19M-C$0.89N/A
Microbix BiosystemsC$15.40M2.62C$3.39M-C$0.04N/A

Summary

Microbix Biosystems beats ImmunoPrecise Antibodies on 7 of the 12 factors compared between the two stocks.

How does Microbix Biosystems compare to Akumin?

Microbix Biosystems (TSE:MBX) and Akumin (TSE:AKU) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

Microbix Biosystems has a beta of 0.759386, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Akumin has a beta of 0.15, indicating that its stock price is 85% less volatile than the broader market.

0.2% of Microbix Biosystems shares are owned by institutional investors. Comparatively, 30.3% of Akumin shares are owned by institutional investors. 14.0% of Microbix Biosystems shares are owned by company insiders. Comparatively, 33.0% of Akumin shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Microbix Biosystems has higher earnings, but lower revenue than Akumin. Microbix Biosystems is trading at a lower price-to-earnings ratio than Akumin, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbix BiosystemsC$15.40M2.62C$3.39M-C$0.04N/A
AkuminC$737.69M0.00-C$255.80M-C$3.80N/A

Microbix Biosystems has a net margin of -31.72% compared to Akumin's net margin of -34.67%. Microbix Biosystems' return on equity of -18.83% beat Akumin's return on equity.

Company Net Margins Return on Equity Return on Assets
Microbix Biosystems-31.72% -18.83% 3.82%
Akumin -34.67%-483.86%0.47%

In the previous week, Microbix Biosystems had 3 more articles in the media than Akumin. MarketBeat recorded 3 mentions for Microbix Biosystems and 0 mentions for Akumin. Microbix Biosystems' average media sentiment score of 0.94 beat Akumin's score of 0.00 indicating that Microbix Biosystems is being referred to more favorably in the media.

Company Overall Sentiment
Microbix Biosystems Positive
Akumin Neutral

Summary

Microbix Biosystems beats Akumin on 8 of the 12 factors compared between the two stocks.

How does Microbix Biosystems compare to GeneNews?

Microbix Biosystems (TSE:MBX) and GeneNews (TSE:GEN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

0.2% of Microbix Biosystems shares are owned by institutional investors. 14.0% of Microbix Biosystems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Microbix Biosystems has higher revenue and earnings than GeneNews. Microbix Biosystems is trading at a lower price-to-earnings ratio than GeneNews, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbix BiosystemsC$15.40M2.62C$3.39M-C$0.04N/A
GeneNewsC$234.59K0.00-C$11.56M-C$0.07N/A

GeneNews has a net margin of 0.00% compared to Microbix Biosystems' net margin of -31.72%. GeneNews' return on equity of 0.00% beat Microbix Biosystems' return on equity.

Company Net Margins Return on Equity Return on Assets
Microbix Biosystems-31.72% -18.83% 3.82%
GeneNews N/A N/A N/A

In the previous week, Microbix Biosystems had 3 more articles in the media than GeneNews. MarketBeat recorded 3 mentions for Microbix Biosystems and 0 mentions for GeneNews. Microbix Biosystems' average media sentiment score of 0.94 beat GeneNews' score of 0.00 indicating that Microbix Biosystems is being referred to more favorably in the media.

Company Overall Sentiment
Microbix Biosystems Positive
GeneNews Neutral

Summary

Microbix Biosystems beats GeneNews on 8 of the 11 factors compared between the two stocks.

How does Microbix Biosystems compare to LED Medical Diagnostics?

Microbix Biosystems (TSE:MBX) and LED Medical Diagnostics (CVE:LMD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Microbix Biosystems has higher revenue and earnings than LED Medical Diagnostics. LED Medical Diagnostics is trading at a lower price-to-earnings ratio than Microbix Biosystems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbix BiosystemsC$15.40M2.62C$3.39M-C$0.04N/A
LED Medical DiagnosticsC$14.96M1.04-C$1.51M-C$0.04N/A

In the previous week, Microbix Biosystems had 3 more articles in the media than LED Medical Diagnostics. MarketBeat recorded 3 mentions for Microbix Biosystems and 0 mentions for LED Medical Diagnostics. Microbix Biosystems' average media sentiment score of 0.94 beat LED Medical Diagnostics' score of 0.00 indicating that Microbix Biosystems is being referred to more favorably in the media.

Company Overall Sentiment
Microbix Biosystems Positive
LED Medical Diagnostics Neutral

LED Medical Diagnostics has a net margin of 0.00% compared to Microbix Biosystems' net margin of -31.72%. LED Medical Diagnostics' return on equity of 0.00% beat Microbix Biosystems' return on equity.

Company Net Margins Return on Equity Return on Assets
Microbix Biosystems-31.72% -18.83% 3.82%
LED Medical Diagnostics N/A N/A N/A

0.2% of Microbix Biosystems shares are held by institutional investors. 14.0% of Microbix Biosystems shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Microbix Biosystems beats LED Medical Diagnostics on 10 of the 12 factors compared between the two stocks.

How does Microbix Biosystems compare to LexaGene?

LexaGene (CVE:LXG) and Microbix Biosystems (TSE:MBX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

In the previous week, Microbix Biosystems had 3 more articles in the media than LexaGene. MarketBeat recorded 3 mentions for Microbix Biosystems and 0 mentions for LexaGene. Microbix Biosystems' average media sentiment score of 0.94 beat LexaGene's score of 0.00 indicating that Microbix Biosystems is being referred to more favorably in the news media.

Company Overall Sentiment
LexaGene Neutral
Microbix Biosystems Positive

0.1% of LexaGene shares are owned by institutional investors. Comparatively, 0.2% of Microbix Biosystems shares are owned by institutional investors. 17.9% of LexaGene shares are owned by insiders. Comparatively, 14.0% of Microbix Biosystems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

LexaGene has a beta of 2.26, indicating that its share price is 126% more volatile than the broader market. Comparatively, Microbix Biosystems has a beta of 0.759386, indicating that its share price is 24% less volatile than the broader market.

LexaGene has a net margin of 0.00% compared to Microbix Biosystems' net margin of -31.72%. Microbix Biosystems' return on equity of -18.83% beat LexaGene's return on equity.

Company Net Margins Return on Equity Return on Assets
LexaGeneN/A -339.54% -120.21%
Microbix Biosystems -31.72%-18.83%3.82%

Microbix Biosystems has higher revenue and earnings than LexaGene. Microbix Biosystems is trading at a lower price-to-earnings ratio than LexaGene, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LexaGeneC$110.93K133.13-C$8.54M-C$0.08N/A
Microbix BiosystemsC$15.40M2.62C$3.39M-C$0.04N/A

Summary

Microbix Biosystems beats LexaGene on 8 of the 13 factors compared between the two stocks.

Get Microbix Biosystems News Delivered to You Automatically

Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBX vs. The Competition

Export
MetricMicrobix BiosystemsLife Sciences Tools & Services IndustryHealthcare SectorTSE Exchange
Market CapC$40.41MC$10.52BC$7.32BC$12.53B
Dividend Yield2.30%1.45%2.52%6.28%
P/E Ratio-8.1975.22274.3939.99
Price / Sales2.62109.57688.889.14
Price / Cash4.1327.9077.8082.29
Price / Book1.646.0810.474.67
Net IncomeC$3.39MC$56.67BC$3.49BC$299.09M
7 Day Performance-1.67%3.29%-0.91%-0.37%
1 Month Performance-1.67%3.38%-4.21%-2.74%
1 Year Performance9.26%40.71%16.39%19.83%

Microbix Biosystems Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MBX
Microbix Biosystems
N/AC$0.30
-1.7%		N/A+5.4%C$40.41MC$15.40MN/AN/A
IPA
ImmunoPrecise Antibodies
N/AC$6.50
+0.8%		N/A+0.0%C$162.08MC$19.47MN/A80
AKU
Akumin
N/AN/AN/AN/AC$37.20MC$737.69MN/A1,527
GEN
GeneNews
N/AN/AN/AN/AC$25.49MC$234.59KN/A2,700
LMD
LED Medical Diagnostics
N/AC$0.40
+∞		N/A+0.0%C$15.51MC$14.96MN/A46

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:MBX) was last updated on 9/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel